Pre-eclampsia is a disorder of high blood pressure that causes decrease in blood supply to the growing foetus. The disease can be severe if left untreated, and can cause seizure or coma to the patient, a condition called as eclampsia. One of the complication associated with pre-eclampsia is HELLP syndrome which is characterized by low platelet count, hemolysis, and elevated liver enzymes. Some of the risk associated with pre-eclampsia that affects foetus are lack of nutrients and oxygen, preterm birth, and stillbirth. According to the Preeclampsia Foundation, each year, around 10,500 infants die in the U.S. A1M Pharma AB is in the process of developing A1M as a free radical scavenger, for the treatment of pre-eclampsia. VG Life Sciences Inc. is also in the process of developing VG 1177 as an immunomodulator, for the treatment of pre-eclampsia. Some of the companies and universities having the pipeline of pre-eclampsia include University of Pittsburgh, VG Life Sciences Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.